Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
Ewing, NJ – June 14, 2023 – Orcosa Inc. (“Orcosa” or the “Company”), a clinical-stage life sciences company improving patient outcomes through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – today announced that the United States Patent and Trademark Office (USPTO) has granted Orcosa a pioneering patent for cannabidiol (CBD) delivered via oral mucosal absorption for the treatment of pain.
The USPTO issued U.S. Patent No. 11,672,761, covering both the composition and the clinical dosing regimen of ORAVEXX™ (CBD) currently being utilized in ongoing clinical trials for patients suffering from acute and chronic pain. This is Orcosa’s first patent granted using the RITe™ Platform, and encompasses claims including composition of matter, formulation, and method of use. ORAVEXX™was recently used in a study led by researchers in the Department of Orthopedic Surgery at NYU Grossman School of Medicine that found that ORAVEXX™ safely managed pain after arthroscopic rotator cuff surgery, and did not produce side effects often associated with CBD use, such as nausea, anxiety, and liver toxicity. The press release announcing the results can be read here.
Orcosa has filed supplementary patent applications in other key global markets and numerous applications are pending for additional active ingredients and indications utilizing the RITe™ Platform in the U.S.
Vincent T. Mileto, Lead Inventor, Co-Founder and Chief Operating Officer of Orcosa commented, “This patent represents a seminal moment for Orcosa and our proprietary drug delivery technology platform. With this achievement, our dedicated team is one step closer to ensuring safer, more effective treatments become a reality for those in need.”
Robert M. Pollaro, Co-Founder and Chief Legal Officer of Orcosa added, “This patent sets the foundation for our RITe™ Platform technology and is an important milestone in protecting the commercial potential of our innovative products. We are confident that this is the first of many on our way to delivering on our mission to improve patient outcomes.”
About ORAVEXX™
ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. Historically, research on the effects of CBD has been limited by a variety of issues including inaccurate dosing, low bioavailability, difficult administration, and a lack of GMP-manufactured products with matching placebos with which to conduct clinical research. ORAVEXX™ is being developed to address these issues associated with unreliable and inefficient orally delivered CBD and provide researchers the opportunity to evaluate CBD more accurately in clinical trials.
About Orcosa Inc.
Orcosa is a life sciences company modernizing the way medicines are taken by combining cutting edge drug delivery with targeted therapeutics to improve patient outcomes. The company has developed the proprietary Rapid Infusion Technology (RITe™) Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa is building a robust pipeline of therapies utilizing the RITe™ Platform to provide transformative medicines for people with chronic and serious diseases. For more information on Orcosa, please visit https://www.orcosa.com.
Forward-Looking Statements
Certain statements made herein constitute “forward-looking statements”. These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Contacts
Devin BrodaFGS GlobalDevin.Broda@fgsglobal.com212-687-8080Investor ContactIR@orcosa.com